The pH-Responsive Liposomes—The Effect of PEGylation on Release Kinetics and Cellular Uptake in Glioblastoma Cells

Abstract

Nanomedicine has been, to a certain degree, a success story in the development of superior anticancer therapies. However, there are tumors that remain a huge challenge for nanoformulations, for instance, brain tumors such as glioblastoma, the most common and aggressive brain tumor. To utilize the fact that such tumors are characterized by an acidic extracellular environment, we selected pH-responsive liposomes as a potential drug delivery system for superior delivery to GBM. Liposomes comprising PEGylated lipid of two chain lengths with encapsulated fluorescent marker calcein were characterized and challenged against non-PEGylated vesicles. The in vitro calcein release from three liposomal formulations (<200 nm), namely non-PEGylated (pH-Lip) and PEGylated, pH-Lip–PEG750, and pH-Lip–PEG2000, was followed at three pH conditions to prove the pH-responsiveness. The intracellular delivery of a liposomally encapsulated marker was determined in GL261 glioblastoma cell lines in vitro using both flow cytometry and confocal microscopy. The inclusion of PEG2000 within liposomal formulation resulted in reduced in vitro pH-responsiveness compared to pH-Lip and pH-Lip750. All three pH-responsive liposomal formulations improved intracellular uptake in GL261 cells compared to non-pH-responsive liposomes, with negligible differences regarding PEG length. The proposed formulations should be further evaluated in glioblastoma models.

Targeted Glioblastoma Treatment via Synthesis and Functionalization of Gold Nanoparticles With De Novo–Engineered Transferrin-Like Peptides: Protocol for a Novel Method

“…We propose coating AuNPs with polyethylene glycol to enhance their stability and biocompatibility [ 15 , 22 ]. Temozolomide, a chemotherapeutic agent, would be either attached to the surface of the AuNPs or could be encapsulated within them [ 4 , 12 ].…”

Enhancing the efficacy of letrozole-loaded PEGylated nanoliposomes against breast cancer cells: In vitro study

“…The specific impact of PEGylation on cellular uptake can vary depending on factors such as the length of the PEG chain. For instance, research comparing liposomes with different PEG chain lengths (e.g., PEG750 and PEG2000) has demonstrated that longer PEG chains may reduce pH responsiveness but not necessarily decrease cellular uptake [ 42 ].…”

PEGylated liposomes enhance the effect of cytotoxic drug: A review

“…Nowadays, PEG has been approved by the FDA as a vehicle in many preparations including pharmaceuticals. Incorporation of longer chain PEG reduces the pH responsiveness of PEGylated liposome, although the uptake of cell toward the higher molecules of PEG is low [ 11 ]. PEG lacks immunogenic reactions and toxicity.…”

“…As a result, PEGylated liposomes will not only improve drug bioavailability and reduce drug concentration but also provide excellent cancer cell targeting. However, adverse effects remain unavoidable even when a nanoparticulate drug delivery method is used [ 32 ] and role of PEG in cell interaction and drug release is still at debate [ 11 , 33 ]. Doxil® consists of a liquid suspension of unilamellar vesicles with size ranges from 80 to 90 nm ( Fig.…”

“…To overcome this limitation, some researchers combined doxorubicin with other drugs. Recent studies on other drugs showed that the use of PEGylated liposomes had improved the delivery of some cytotoxic agents [ 3 , 11 ].…”